KIF11 and gastric adenocarcinoma: Seven newly synthetized Eg5 inhibitors were already tested on gastric adenocarcinoma cell line and two of them, 2 and 41, were chosen for their promising in vitro effects in counteracting tumor cell viability and in negatively modulating angiogenic cascade [24,25].